Fig. 6From: Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapyStability of the radiopeptide over time, in the presence and absence of ascorbic acid: the graph shows the % intact 161Tb/177Lu-DOTATOC over a period of 24 h. In the presence of ascorbic acid 177Lu and 161Tb-DOTATOC curves overlap, making it impossible to visualize both simultaneouslyBack to article page